Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMPLIFON S.P.A.

(AMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amplifon S.p.A. : No turn-around in sight

long trade
Live
Entry price : 41.46€ | Target : 51€ | Stop-loss : 35€ | Potential : 23.01%
Shares in Amplifon S.p.A. do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the € 51.
Amplifon S.p.A. : Amplifon S.p.A. : No turn-around in sight
Strengths
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.

Weaknesses
  • With an expected P/E ratio at 55.82 and 47.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • With an enterprise value anticipated at 5.27 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company is not the most generous with respect to shareholders' compensation.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart
Subsector Other Medical Equipment, Supplies & Distribution
1st jan.Capitalization (M$)Investor Rating
AMPLIFON S.P.A.26.67%10 927
ABBOTT LABORATORIES14.87%226 394
MEDTRONIC PLC-8.91%148 311
BECTON, DICKINSON AND COMPA..-5.23%69 191
HOYA CORPORATION26.28%58 287
DEXCOM, INC.52.17%55 343
SARTORIUS STEDIM BIOTECH76.24%53 316
ALIGN TECHNOLOGY, INC.14.44%50 030
BAXTER INTERNATIONAL INC.-7.07%38 068
WEST PHARMACEUTICAL SERVICE..56.25%33 142
TERUMO CORPORATION7.33%31 960
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 1 966 M 2 228 M 2 228 M
Net income 2021 170 M 192 M 192 M
Net Debt 2021 1 253 M 1 420 M 1 420 M
P/E ratio 2021 56,8x
Yield 2021 0,51%
Capitalization 9 694 M 10 927 M 10 988 M
EV / Sales 2021 5,57x
EV / Sales 2022 4,93x
Nbr of Employees 11 265
Free-Float 53,8%
Upcoming event on AMPLIFON S.P.A.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 43,12 €
Average target price 42,22 €
Spread / Average Target -2,10%
EPS Revisions
Managers and Directors
Enrico Vita Chief Executive Officer & Executive Director
Gabriele Galli Chief Financial Officer
Susan Carol Holland Chairman
Andrea Ciccolini Chief Information Officer
Maurizio Costa Independent Non-Executive Director